Wave Life Sciences: director Adrian Rawcliffe received 74,700 shares

What happened Adrian Rawcliffe, a director of Wave Life Sciences, was granted 10,700 restricted stock units (RSUs) and a 64,000-share option (derivative) on Oct 5, 2026. Both grants are reported with a price per share of $0.

Key details

• Transaction date(s) and price(s): Oct 5, 2026; RSU 10,700 shares @ $0; option 64,000 shares (derivative) @ $0.
• Shares owned after the transaction: not provided in the filing excerpt supplied.
• Footnotes: F1 — the 10,700 RSU vests 100% on the earlier of the Company's 2027 annual meeting of stockholders or Oct 5, 2027. F2 — the 64,000-share option vests 100% on the earlier of the Company's 2027 annual meeting of stockholders or Oct 5, 2027. Both grants were made under the 2026 Non-Employee Director Compensation Policy.
• Filing timeliness: not indicated in the filing excerpt supplied.

Why it may matter

• These transactions are grants/awards, not open-market purchases or sales.
• The 64,000-share item is an option grant (derivative), not an issuance of marketable shares at the time of the filing.
  A filing does not show why the insider traded or why the company acted.